SciSparc (SPRC) Surges 59% on Quantum Computing Breakthrough: Is This the Dawn of a New Era in Drug Discovery?

Summary
• SciSparc’s stock (SPRC) rockets 59% intraday, surging from $5.25 to $8.90 in a historic move.
• The company unveils a quantum computing initiative for 3D protein modeling, signaling a paradigm shift in drug discovery.
• Turnover skyrockets 16,428% as retail and institutional investors flock to the biotech story.

SciSparc’s (SPRC) stock has ignited a frenzy, surging 59% in a single session amid a groundbreaking quantum computing initiative. The biotech sector, typically cautious, is now abuzz with speculation as the company’s bold foray into quantum-enabled drug discovery challenges conventional R&D models. With a $9.88M market cap and a 52-week range of $1.75–$37.59, SPRC’s volatility underscores the high-stakes gamble on cutting-edge science.

Quantum Computing Initiative Ignites SciSparc's Record Surge
SciSparc’s (SPRC) meteoric rise stems from its board’s resolution to launch a quantum computing initiative for 3D protein modeling. By integrating quantum algorithms into structural biology, the company aims to simulate protein dynamics with unprecedented precision, accelerating drug discovery for neurological and rare diseases. This initiative, backed by a new Israeli subsidiary and collaborations with quantum computing experts, positions SciSparc at the forefront of a technological revolution. The market’s reaction reflects optimism that quantum computing could overcome classical limitations in modeling protein conformations, a critical hurdle in pharmaceutical innovation.

Technical Analysis and ETF Strategy: Navigating SPRC’s Volatility
• RSI: 66.35 (overbought, suggesting potential pullback)
• MACD: -0.021 (bullish histogram at 0.31)
• Bollinger Bands: Upper at $5.14, Middle at $2.89, Lower at $0.65 (price at $6.09, above upper band)
• 200D MA: $1.72 (far below current price)

SciSparc’s (SPRC) technicals paint a picture of extreme short-term bullish momentum. The RSI’s overbought level and MACD’s positive divergence hint at a potential consolidation phase, but the Bollinger Bands’ breakout suggests continued upward pressure. Traders should monitor the $6.09 level as a critical support; a break below could trigger a retest of the $5.25 intraday low. While no leveraged ETFs are available, the biotech sector’s mixed performance (Amgen’s AMGN down 2.86%) adds caution. No options data exists to evaluate, but a bullish strategy could involve a tight stop-loss above the $5.25 low to capture the next leg higher.

Backtest SciSparc Stock Performance
Based on your request, I’ve completed a strategy back-test that buys SciSparc (SPRC) at each trading-day close when the same-day gain is ≥ 59 %, then holds for up to 10 trading days (or until either a 200 % take-profit or a 20 % stop-loss is hit). I’ve prepared an interactive results panel so you can inspect the equity curve, trade log, and key statistics.Please open the panel to explore detailed metrics such as total return, win rate, average trade P&L, maximum drawdown, and the full trade list.Notes:1. Dates with 59 %+ closes were auto-detected from 2022-01-01 through 2025-09-25 using SPRC daily prices (file sprc_daily_ohlc_2022_present.json).2. Default risk controls (20 % stop-loss, 200 % take-profit, 10-day max hold) were chosen to bound extreme volatility; feel free to ask for different thresholds if desired.Let me know if you would like additional scenarios (e.g., different profit/stop levels, no risk controls, or alternative hold periods) or further interpretation of the results.

Seize the Quantum Opportunity: SPRC’s Breakthrough Could Reshape Biotech—But Act Fast
SciSparc’s (SPRC) quantum computing initiative represents a high-risk, high-reward bet on the future of drug discovery. The stock’s technicals and news-driven momentum suggest a continuation of the rally, but volatility remains a double-edged sword. Investors should watch the $6.09 level as a key inflection point and track Amgen’s (AMGN) -2.86% decline for sector sentiment. For those with a high-risk appetite, a disciplined approach to entry and exit levels could capitalize on this biotech revolution. The question isn’t whether SPRC can sustain its surge—it’s whether the market will embrace its quantum leap before the next wave of innovation.